Navigation Links
OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Date:11/15/2012

ay cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. 


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
2. OncoSec to Present at Upcoming Healthcare and Investor Conferences
3. OncoSec Granted New Patent from China
4. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
5. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
6. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
7. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
8. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
9. OncoSec Medical Issues Letter to Shareholders
10. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
11. Patient and Disability Groups Support Bill to Begin Market Pricing System for Home Medical Equipment in Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8ZEISS Asserts its Position in Difficult Environment 2
... May 21, 2007/PRNewswire-FirstCall/ -- Bristol-Myers,Squibb Company (NYSE: ... which showed that treatment with Baraclude (entecavir),demonstrated ... 48 weeks,-- a result that was also ... These data from an open-label, randomized viral ...
... -- Data presented,today at a major medical meeting ... for five days is as,effective as standard therapy ... treatment of complicated urinary tract infections,(cUTI) and acute ... markets LEVAQUIN in the,U.S., presented the data during ...
Cached Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4
(Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
(Date:12/21/2014)... Columbus, OH (PRWEB) December 21, 2014 ... of men alleging heart attacks, stroke and blood clots ... continue to increase, a new study shows that the ... developing colon cancer. In a study published in the ... lead researcher, James Amos-Landgraf examined a group of male ...
(Date:12/21/2014)... December 21, 2014 The Oncology Institute of ... the Santa Ana and Whittier offices. The Hope for the ... lives of patients and their families during the holiday season. ... to approximately 70 children between both offices. This event continues ... of Target’s community service team, store managers and assistant managers ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many ... recently shown its new engineered bamboo flooring collection, and ... models. , BambooIndustry.com’s customers come from many countries in ... to the CEO of the company, the global bamboo ... past few years, and the demand for eco-friendly bamboo ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just done ... drastically cut prices to all its prom dresses already, ... 2015. Many of the hottest styles are sold here ... and more. , A spokesman for MissyDress says, “The ... princess prom dresses or sweetheart chiffon prom dresses, you ...
Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... emergence of minimally invasive surgery procedures in operating theatres. ... leaves much to be desired. Researcher Magdalena Chmarra has ... training system which records and analyses the surgeon,s movements. ... time, an objective benchmark for measuring a surgeon,s basic ...
... ICU, and All-Private Hospital WingNEW ORLEANS, Jan. 12 At ... on Monday, January 12, 2009 , DHH Secretary Alan ... Ochsner Baptist Medical Center and the community to celebrate the ... room hospital wing at 2700 Napoleon Avenue in ...
... NEW YORK and SAN FRANCISCO, Jan. 12 ... the largest independent communications agency focused exclusively on ... focused on helping companies build health-based brands, today ... services agency that works with healthcare and technology ...
... AMERIGROUP Corporation (NYSE: AGP ) announced ... Institute, which will enhance the Company,s focus on improving ... are financially vulnerable, who have disabilities or who are ... a joint venture of AMERIGROUP Corporation and the AMERIGROUP ...
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... medical devices worldwide, today announced selected preliminary,unaudited results ... The,preliminary results reported below include the results ... Datascope ("DPM") starting from May,1, 2008. , ...
... Bioequivalence Study to Evaluate the Safety, Tolerability, and ... Laboratories, Inc, an emerging specialty pharmaceutical company dedicated ... in opioid pharmaceuticals, announced today the initiation of ... CL-108. "After many months, development in the ...
Cached Medicine News:Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2Health News:Ochsner Baptist Opens ER and Clara Wing 2Health News:Ochsner Baptist Opens ER and Clara Wing 3Health News:Ochsner Baptist Opens ER and Clara Wing 4Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 2Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 3Health News:AMERIGROUP to Establish Public Policy Institute 2Health News:AMERIGROUP to Establish Public Policy Institute 3Health News:Mindray Announces Preliminary 2008 Operating Results 2Health News:Mindray Announces Preliminary 2008 Operating Results 3Health News:Mindray Announces Preliminary 2008 Operating Results 4Health News:Charleston Laboratories, Inc. Phase I Clinical Trial 2
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: